GSK spinout SR One collects $500m for fund
SR One, a biotech venture firm that recently spun out from GlaxoSmithKline, has raised $500 million for its new fund.
SR One, a biotech venture firm that recently spun out from GlaxoSmithKline, has raised $500 million for its new fund.
Copyright PEI Media
Not for publication, email or dissemination